Aprogen pharmaceuticals,Inc.
KRX:003060.KS
953 (KRW) • At close September 6, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) KRW.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 87,363.628 | 65,190.359 | 56,481.702 | 53,319.976 | 50,903.821 | 45,395.389 | 46,100.952 | 44,122.493 | 40,324.275 | 33,092.222 | 29,543.262 | 33,769.678 | 50,122.955 | 16,689.083 | 62,227.816 | 21,137.045 | 17,117.086 |
| Cost of Revenue
| 99,409.252 | 37,904.192 | 31,036.787 | 30,119.001 | 30,345.342 | 26,614.62 | 27,269.769 | 25,497.338 | 25,241.49 | 22,235.831 | 21,107.91 | 23,419.498 | 25,355.645 | 6,939.729 | 31,871.872 | 14,830.907 | 9,294.876 |
| Gross Profit
| -12,045.624 | 27,286.167 | 25,444.915 | 23,200.976 | 20,558.478 | 18,780.769 | 18,831.183 | 18,625.154 | 15,082.785 | 10,856.391 | 8,435.353 | 10,350.18 | 24,767.31 | 9,749.354 | 30,355.944 | 6,306.138 | 7,822.21 |
| Gross Profit Ratio
| -0.138 | 0.419 | 0.45 | 0.435 | 0.404 | 0.414 | 0.408 | 0.422 | 0.374 | 0.328 | 0.286 | 0.306 | 0.494 | 0.584 | 0.488 | 0.298 | 0.457 |
| Reseach & Development Expenses
| 14,999.891 | 2,186.845 | 1,735.386 | 697.701 | 336.12 | 191.622 | 180.185 | 84.54 | 135.382 | 44.764 | 105.264 | 339.099 | 491.061 | 321.713 | 836.029 | 349.263 | 775.644 |
| General & Administrative Expenses
| 2,986.604 | 3,277.935 | 3,702.015 | 3,717.296 | 3,826.653 | 3,314.211 | 3,588.854 | 3,050.088 | 2,229.932 | 1,977.555 | 2,504.951 | 2,266.958 | 1,783.72 | 433.861 | 1,146.442 | 798.213 | 882.56 |
| Selling & Marketing Expenses
| 15,567.018 | 14,558.008 | 10,728.712 | 7,536.058 | 7,003.653 | 5,747.52 | 5,916.324 | 5,173.433 | 3,977.618 | 5,668.712 | 4,161.008 | 5,745.248 | 8,666.053 | 3,344.386 | 11,995.044 | 2,933.015 | 2,669.753 |
| SG&A
| 43,644.537 | 17,835.943 | 14,430.727 | 11,253.354 | 10,830.306 | 9,061.731 | 9,505.178 | 8,223.521 | 6,207.55 | 7,646.267 | 6,665.959 | 8,012.206 | 10,449.773 | 3,778.247 | 13,141.486 | 3,731.228 | 3,552.313 |
| Other Expenses
| 225.536 | 12,975.533 | 13,077.975 | 12,222.219 | 11,322.444 | 98.116 | -5,333.378 | -319.907 | -191.661 | 6.667 | -3,274.28 | -724.573 | 178.758 | -270.614 | -2,183.756 | -3,642.42 | -5,154.204 |
| Operating Expenses
| 58,644.428 | 32,998.321 | 29,244.088 | 24,173.274 | 22,488.87 | 19,606.355 | 20,288.786 | 18,872.527 | 15,949.093 | 16,208.776 | 21,985.906 | 26,743.536 | 24,304.722 | 8,480.835 | 26,366.586 | 10,450.711 | 9,560.022 |
| Operating Income
| -70,690.052 | 12,808.544 | 10,488.328 | 13,952.3 | -1,930.392 | -825.585 | -1,457.602 | -247.372 | -866.308 | -5,352.386 | -13,550.554 | -16,393.357 | 820.865 | 1,268.52 | 3,989.356 | -4,144.571 | -1,737.812 |
| Operating Income Ratio
| -0.809 | 0.196 | 0.186 | 0.262 | -0.038 | -0.018 | -0.032 | -0.006 | -0.021 | -0.162 | -0.459 | -0.485 | 0.016 | 0.076 | 0.064 | -0.196 | -0.102 |
| Total Other Income Expenses Net
| 33,843.709 | -5,964.773 | -657.625 | 2,691.381 | -1,126.876 | -9,804.503 | -15,066.448 | -3,246.656 | -738.255 | 975.881 | -7,301.467 | -8,477.606 | -5,022.703 | -1,856.93 | -12,703.661 | -5,401.148 | -8,758.783 |
| Income Before Tax
| -36,846.343 | 6,843.771 | 9,830.703 | 16,643.681 | -3,057.267 | -952.408 | -16,524.051 | -4,051.383 | 1,215.47 | -4,376.504 | -20,852.021 | -24,870.962 | -4,560.115 | -588.411 | -8,714.303 | -9,545.721 | -10,496.595 |
| Income Before Tax Ratio
| -0.422 | 0.105 | 0.174 | 0.312 | -0.06 | -0.021 | -0.358 | -0.092 | 0.03 | -0.132 | -0.706 | -0.736 | -0.091 | -0.035 | -0.14 | -0.452 | -0.613 |
| Income Tax Expense
| 1,947.066 | 1,260.151 | 679.691 | -2,273.889 | 409.257 | 263.005 | 366.861 | 715.564 | -337.16 | 19.387 | 3,541.194 | 5,173.823 | 375.608 | 116.011 | 623.685 | -7,617.554 | 1,618.584 |
| Net Income
| -118,269.721 | 5,583.62 | 8,102.57 | 18,917.57 | -3,466.524 | -1,215.413 | -16,364.749 | -3,917.715 | 2,760.675 | -3,887.365 | -20,852.021 | -24,870.962 | -4,560.115 | -704.422 | -8,097.501 | -5,489.801 | -10,496.595 |
| Net Income Ratio
| -1.354 | 0.086 | 0.143 | 0.355 | -0.068 | -0.027 | -0.355 | -0.089 | 0.068 | -0.117 | -0.706 | -0.736 | -0.091 | -0.042 | -0.13 | -0.26 | -0.613 |
| EPS
| -1,421.09 | 104.07 | 55.98 | 130.7 | -18.73 | -8.03 | -134.55 | -32.13 | 23.43 | -37.49 | -226.25 | -309.25 | -92.8 | -18.07 | -769.46 | -683.05 | -1,979.1 |
| EPS Diluted
| -1,421.09 | 104.07 | 151.99 | 447.15 | -18.73 | -8.03 | -134.55 | -32.13 | 23.43 | -37.49 | -226.25 | -309.25 | -92.8 | -18.07 | -769.46 | -683.05 | -1,979.1 |
| EBITDA
| -49,292.449 | 15,212.529 | 12,560.181 | 15,884.347 | -2,375.064 | 10,318.229 | -6,726.633 | 622.868 | 3,553.204 | -2,996.743 | -16,203.384 | -15,774.714 | -562.562 | -391.025 | -235.564 | -10,025.79 | -6,667.266 |
| EBITDA Ratio
| -0.564 | 0.233 | 0.222 | 0.298 | -0.047 | 0.227 | -0.146 | 0.014 | 0.088 | -0.091 | -0.548 | -0.467 | -0.011 | -0.023 | -0.004 | -0.474 | -0.39 |